ADMA Biologics, Inc. Forecast, price target & analysts
ADMA Biologics, Inc. Target price 2026 - Analyst rating & recommendation
ADMA Biologics, Inc. Classifications & Recommendation
ADMA Biologics, Inc. Price Target
| Target Price | $17.34 |
| Price | $10.18 |
| Potential |
70.33%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target ADMA Biologics, Inc. 2027 .
The average ADMA Biologics, Inc. target price is $17.34.
This is
70.33%
register free of charge
$22.05
116.60%
register free of charge
$12.12
19.06%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend ADMA Biologics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ADMA Biologics, Inc. stock has an average upside potential 2027 of
70.33%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 510.17 | 546.07 |
| 19.63% | 7.04% | |
| EBITDA Margin | 37.55% | 51.17% |
| 14.91% | 36.26% | |
| Net Margin | 28.80% | 32.83% |
| 37.87% | 13.99% |
6 Analysts have issued a sales forecast ADMA Biologics, Inc. 2026 . The average ADMA Biologics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an ADMA Biologics, Inc. EBITDA forecast 2026. The average ADMA Biologics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 ADMA Biologics, Inc. Analysts have issued a net profit forecast 2026. The average ADMA Biologics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.60 | 0.80 |
| 25.93% | 33.33% | |
| P/E | 12.80 | |
| EV/Sales | 4.29 |
6 Analysts have issued a ADMA Biologics, Inc. forecast for earnings per share. The average ADMA Biologics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ADMA Biologics, Inc....
Current ADMA Biologics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 15 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | May 07 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 21 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Apr 13 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| Raymond James |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 15 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 21 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Apr 13 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Mar 26 2026 |
|
Locked
Raymond James:
Locked
➜
Locked
|
May 08 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
